Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
JAGX
JAGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
JAGX News
Virtual Investor Conferences Forum Highlights
Jun 26 2026
Globenewswire
Jaguar Completes Study on Crofelemer for Canine Chemotherapy-Induced Diarrhea
Jun 23 2026
Newsfilter
Jaguar Completes NADA Submission for Canalevia-CA1 in Dogs
Jun 23 2026
Yahoo Finance
Agenda Announced for Life Sciences Virtual Investor Forum
Jun 23 2026
Globenewswire
Jaguar Health Initiates Strategic Review to Enhance Shareholder Value
Jun 22 2026
seekingalpha
Jaguar Health Reports Q1 Earnings Results
May 21 2026
seekingalpha
Jaguar Health Reports 816% Revenue Surge in Q1 2026
May 21 2026
NASDAQ.COM
Jaguar (JAGX) Q4 2025 Earnings Transcript
May 20 2026
NASDAQ.COM
Jaguar Health Announces Investor Webcast and Conference Presentation Dates
May 20 2026
Newsfilter
Jaguar Health Advances Crofelemer Development for Pediatric MVID
May 06 2026
Newsfilter
Geely's Strategic Positioning in the U.S. Market
May 04 2026
CNBC
Jaguar Health Launches Neonorm Dog Product Line
May 04 2026
NASDAQ.COM
Jaguar Health Advances Towards Full FDA Approval of Crofelemer
Apr 29 2026
Newsfilter
Jaguar Health Leverages AI for Crofelemer Treatment Advancement
Apr 14 2026
NASDAQ.COM
Jaguar Health Reports Q4 2025 Earnings Highlights
Apr 11 2026
Yahoo Finance
Jaguar Health Completes Study on Chemotherapy-Induced Diarrhea in Dogs
Apr 08 2026
Newsfilter
Show More News
